Gilead Sciences Stock Cash And Equivalents
| GILD34 Stock | BRL 287.56 4.47 1.58% |
Gilead Sciences fundamentals help investors to digest information that contributes to Gilead Sciences' financial success or failures. It also enables traders to predict the movement of Gilead Stock. The fundamental analysis module provides a way to measure Gilead Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gilead Sciences stock.
Gilead |
Gilead Sciences Company Cash And Equivalents Analysis
Gilead Sciences' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Gilead Sciences Cash And Equivalents | 28.36 B |
Most of Gilead Sciences' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Gilead Sciences has 28.36 B in Cash And Equivalents. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - Major industry. The cash and equivalents for all Brazil stocks is significantly lower than that of the firm.
Gilead Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gilead Sciences' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gilead Sciences could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics of similar companies.Gilead Sciences is rated # 2 in cash and equivalents category among its peers.
Gilead Fundamentals
| Return On Equity | 0.22 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.40 % | |||
| Current Valuation | 686.18 B | |||
| Shares Outstanding | 2.49 B | |||
| Price To Earning | 28.35 X | |||
| Price To Book | 5.30 X | |||
| Price To Sales | 21.27 X | |||
| Revenue | 27.28 B | |||
| Gross Profit | 21.62 B | |||
| EBITDA | 6.75 B | |||
| Net Income | 4.59 B | |||
| Cash And Equivalents | 28.36 B | |||
| Cash Per Share | 22.39 X | |||
| Total Debt | 25.18 B | |||
| Debt To Equity | 117.00 % | |||
| Current Ratio | 3.76 X | |||
| Book Value Per Share | 17.01 X | |||
| Cash Flow From Operations | 9.07 B | |||
| Earnings Per Share | 9.63 X | |||
| Price To Earnings To Growth | 0.71 X | |||
| Number Of Employees | 31 | |||
| Beta | 0.41 | |||
| Market Capitalization | 572.2 B | |||
| Total Asset | 63.17 B | |||
| Z Score | 13.2 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 63.17 B | |||
| Last Dividend Paid | 2.92 |
About Gilead Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gilead Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gilead Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gilead Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Gilead Stock
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.